Effects of a beverage containing an enzymatically induced-viscosity dietary fiber, with or without fructose, on the postprandial glycemic response to a high glycemic index food in humans.
OBJECTIVE
Dietary supplementation with guar gum or fructose has been reported to reduce the postprandial glycemic response to an oral glucose challenge. As a result of the poor palatability of most foods containing guar gum, a novel low-viscosity beverage with guar gum was developed that becomes viscous in vivo through an enzymatic induction. The primary study objective was to determine the effect of an amylase-induced viscosity (I-V) product, with or without supplemental fructose, on the postprandial glycemic response to a high glycemic index test meal in healthy nondiabetic subjects.


METHODS
The study was a four-treatment, placebo-controlled, double-blind, randomized block protocol.


METHODS
The study was performed at Glycaemic Index Testing, Inc., Toronto, Ontario, Canada.


METHODS
A total of 30 healthy nondiabetic volunteers (13 male, 17 female, mean+/-s.e.m. age of 51+/-3 y and body mass index of 24.2+/-0.4 kg/m(2)) participated in the study.


METHODS
In the morning after an overnight fast, subjects participated in four 3-h meal glucose tolerance tests on separate occasions. The test meals contained 50 g of available carbohydrate from maltodextrin and white bread (control) or the same meal with either 5 g of guar gum (3.6 g galactomannan), 5 g of fructose, or 5 g of guar gum +5 g of fructose.


RESULTS
Treatments containing guar gum had a reduced (P<0.01) baseline-adjusted peak glucose response and incremental area under the glucose curve. In contrast to previous studies, fructose increased (P<0.05) the baseline-adjusted peak glucose concentration.


CONCLUSIONS
Guar gum incorporated into an amylase I-V product provided a means to stabilize blood glucose levels by reducing the early phase excursion and then by appropriately maintaining the later phase excursion in healthy nondiabetic humans.
Wolf
B W
BW
Ross Products Division, Abbott Laboratories, Columbus, OH 43215-1724, USA. bryan.wolf@abbott.com
Wolever
T M S
TM
Lai
C S
CS
Bolognesi
C
C
Radmard
R
R
Maharry
K S
KS
Garleb
K A
KA
Hertzler
S R
SR
Firkins
J L
JL
D000293:Adolescent; D000328:Adult; D000368:Aged; D000681:Amylases / Q000008:administration & dosage*; D001628:Beverages; D001786:Blood Glucose / Q000378:metabolism; D004043:Dietary Fiber; D004311:Double-Blind Method; D005260:Female; D005632:Fructose / Q000008:administration & dosage*; D005767:Gastrointestinal Diseases / Q000209:etiology / Q000503:physiopathology; D038321:Glycemic Index / Q000502:physiology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D019518:Postprandial Period / Q000502:physiology*; D012016:Reference Values; D014783:Viscosity
D001786:Blood Glucose; D004043:Dietary Fiber; D005632:Fructose; D000681:Amylases